microRNA-147b (miR-147b)

microRNA-147b (miR-147b) is a small, non-coding regulatory RNA belonging to the microRNA family, encoded in the human genome as hsa-miR-147b or MIR147B. It regulates gene expression post-transcriptionally by binding to complementary sequences within the 3′ untranslated regions (3′ UTR) of target mRNAs, resulting in their silencing or degradation. miR-147b is upregulated in various cancers including lung adenocarcinoma and hepatocellular carcinoma, where its expression correlates with poor prognosis and increased tumor aggressiveness. Mechanistically, miR-147b modulates critical pathways such as MAPK signaling (by targeting DUSP8), the hypoxia response (through inhibition of VHL), and the Wnt/PCP pathway in cancer stemness. In cancer therapy, miR-147b contributes to resistance against EGFR tyrosine kinase inhibitors like osimertinib and gefitinib by promoting cellular adaptations such as pseudohypoxia and stemness; its inhibition may restore drug sensitivity. Additionally, miR-147b regulates vascular endothelial barrier function via repression of ADAM15, with potential roles in vascular biology and inflammation. As a result, it is considered a therapeutic target and a biomarker for disease progression and drug response in oncology and related fields[1][3][4][5].

Other names

hsa-miR-147bMIRN147BMIR147Bmir-147b

Post-transcriptional repression of mRNA targets (via 3′ UTR binding); Modulation of molecular pathways (MAPK signaling, pseudohypoxia/HIF pathway, Wnt/PCP signaling, inhibition of apoptosis suppressors like DUSP8, regulation of VHL/ubiquitin-proteasome system); Impact on gene expression profiles relevant to drug resistance and tumor aggressiveness